Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bull 2X Shares

25.61
+0.19000.75%
Volume:70.07K
Turnover:1.83M
Market Cap:15.37M
PE:- -
High:26.61
Open:25.98
Low:25.23
Close:25.42
52wk High:34.28
52wk Low:11.50
Shares:600.00K
Float Shares:600.00K
Volume Ratio:0.42
T/O Rate:11.68%
Dividend:3.09
Dividend Rate:12.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Benzinga
·
1 hour ago

Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows

Reuters
·
1 hour ago

US STOCKS-Wall St heads for weekly losses as tech jitters offset inflation relief

Reuters
·
2 hours ago

Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia

TIPRANKS
·
3 hours ago

Roche’s New Breast Cancer Trial Pits Its Pipeline Against Eli Lilly’s Standard: What It Means for RHHBY

TIPRANKS
·
3 hours ago

Eli Lilly Prepares for Oral Weight-Loss Drug Market, Building Stockpiles Ahead of FDA Decision

Stock News
·
Yesterday

Insulet Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Yesterday

Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision

Reuters
·
Yesterday

Eli Lilly: Expect Medicare Beneficiaries Will Have Access to Discounted Lilly Obesity Medicines by July 1, 2026

THOMSON REUTERS
·
Yesterday

Eli Lilly: Pre-Launch Inventories Capitalized as of Dec 31, 2025 Were $1.5 Bln, Primarily Related to Orforglipron- SEC Filing

THOMSON REUTERS
·
Yesterday

Eli Lilly posts FY 2025 net income of USD 20.64 billion, up nearly double

Reuters
·
Yesterday

Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings

TIPRANKS
·
Yesterday

BUZZ-Jefferies lifts Novo Nordisk to 'hold,' sees downside risks now priced in

Reuters
·
Feb 12

Novo Nordisk plans to launch Wegovy vials

Reuters
·
Feb 12

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 12

More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds

Reuters
·
Feb 12

CICC Adjusts Price Target on Eli Lilly and Co. to $1,107 From $1,060, Maintains Neutral Rating

MT Newswires Live
·
Feb 11

Eli Lilly's Intestinal Disease Treatment Mirikizumab Receives Approval in China

Stock News
·
Feb 11

Eli Lilly: Mirikizumab Approved in China for Treatment of Moderate-to-Severe Crohn's Disease and Ulcerative Colitis - Co Statement

THOMSON REUTERS
·
Feb 11